Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - EU Market Recap: FTSE 100 +0.08% to 7548.44, DAX (0.15%) to 16766.05, CAC40 (0.16%) to 7531.22, STOXX 600 (0.06%) to 472.46

Dec 13 ,2023

  • Synopsis:

    • European markets ended mostly mixed. Italy and UK firmer. Chemicals, healthcare and utilities the best performers whilst telecom, autos/parts and retail the main laggards.

    • Focus on Fed policy decision. Dovish rate outlook set to be tested by Fed's updated SEP with markets still betting on ~100 bp of rate cuts next year following softer-than-expected US core CPI.

    • In politics, German government reached an agreement on 2024 budget to plug €17B hole, after weeks of negotiations whilst UK PM Sunak's flagship legislation on handling of illegal immigration passed first commons vote.

    • On the macro-calendar, UK monthly activity data for October showed a deeper-than-expected contraction with GDP down (0.3%) versus forecast for a (0.1%) drop and +0.2% growth in September. Oct Industrial Production growth also decelerating to +0.4% y/y vs consensus +1.1% and prior +1.5% whilst trade deficit wider-than-expected at £17.03B versus consensus £14.3B and prior £14.29B due to +8.2% increase in imports, while exports up +1.2%. Oct Construction Output recorded at +1.1% y/y vs consensus +1.2% and prior +2.8%. Overall, data reflects economy struggling into Q4 as prior rate hikes weigh on activity. Eurozone Oct industrial production slows down faster than forecast (6.6%) y/y vs consensus (4.6%).

    • On the corporate front, Inditex (ITX.SM) reported 9M earnings and issued FY23 guidance indicating that it expects FY2023 gross margin of around 75 bps higher than in FY2022 vs prior guidance of stable gross margin (+/-50bps). In Nordics, Storebrand (STB.NO) presented the group's strategic direction and financial ambitions towards 2025 in connection with today's CMD, targeting ROE of 14%. Also, DFDS (DFDS.DC) presented its updated strategy and financial ambitions for 2024-2026, aiming at ROIC increase to at least 10% by 2026 from the current level of around 8%. Out of the UK, Gulf Keystone Petroleum (GKP.LN) and Cohort (CHRT.LN) and Bushveld Minerals (BMN.LN) are among other companies from the region to update investors with their latest numbers. Elsewhere, Dalata Hotel Group (DHG.ID) issued a trading update and said to anticipate adjusted EBITDA for the year in excess of €220M vs FactSet €218M whilst Flughafen Wien (FLU.AV ) reported Nov Group total passenger traffic +13.8% to ~2.67M.

    • On the M&A news flow, Vertex has commenced a public tender offer for 100% of the shares of Pagero (PAGERO.SS) at a price of SEK36 in cash per share, equivalent to a total tender value of $555M. Heather Global plc (Bidco), HeadFirst Global B.V. reached agreement on the terms of a recommended offer for Impellam (IPEL.LN) at 557.2 pence in cash and392.8 pence in principal amount of loan notes. Also, EQS Group (EQS.GR) boards recommended accepting the public takeover offer by Thoma Bravo at €40/share in cash whilst SII ( SII.FP) received a €70/share buyout offer from group including chairman, CEO.

    • In rumoured deals, press reports suggest Italy's government exploring options for taking control of Telecom (TIT.IM) Sparkle business, International Distributions Services (IDS.LN) may offer up to €500M (£429.6M) for Packeta whilst Fresenius Medical Care pushed back final bids deadline for Cura Group until next week.

    • Looking ahead to tomorrow's EU econ-calendar, notable releases will include, amongst others, Spain Nov final CPI, Switzerland Nov PPI and UK Nov house price balance - RICS. Of note, tomorrow focus on central banks policy statements: SNB at 3:30 ET, followed by BOE at 7:00 ET, ECB (8:15 ET) and press conference (8:45 ET).

  • Digest:

    • Sectors - STOXX Europe 600:

      • Outperformers

        • Chemicals +1.14%, Health Care +0.80%, Utilities +0.72%, Real Estate+0.49%, Persnl & HHold Goods +0.07%, Technology (0.02%), Construct & Mtls (0.03%)

      • Underperformers

        • Telecom (1.29%), Autos & Parts (0.89%), Retail (0.86%), Basic Resources (0.74%), Travel & Leisure (0.73%), Food & Beverage (0.44%), Ind Goods & Svcs (0.33%), Media (0.32%), Banks (0.35%), Insurance (0.20%), Oil & Gas (0.20%), Financial Svcs (0.06%), Construct & Mtls (0.07%)

    • Macro:

      • EU

        • EU to unblock €10B for Hungary ahead of Ukraine summit -- FT

        • France seeks weaker EU due diligence rules for banks -- FT

      • UK

        • UK economy shrinks unexpectedly as households feel squeeze -- Guardian

      • Germany

        • Germany clinches last-minute 2024 budget deal, sticks to debt brake -- Reuters

        • German exports to CIS countries soar in first 10 months of 2023 -- Reuters

      • Italy:

        • Italy could veto deal on EU stability pact rules - Meloni -- ReutersSp

    • Company news:

      • Notable Gainers

        • +70.0% PAGERO.SS (Pagero Group SEK35.60, +14.70) -- Vertex, Inc (VERX) offers SEK36/share in cash for Pagero Group

        • +36.9% IPEL.LN (Impellam Group £8.70, +2.40) -- Heather Global plc (Bidco), HeadFirst Global B.V. reach agreement on the terms of a recommended offer for Impellam

        • +31.4% SII.FP (SII SA €69.30, +16.60) -- receives €70/share buyout offer from group including chairman, CEO

        • +27.9% EAS2P.NA (Ease2pay €0.73, +0.16) -- expects a positive EBITDA for 2024

        • +14.4% GIGA.NO (Gigante Salmon NOK8.26, +1.08) -- initiated buy at Sparebank 1 Markets

        • +13.4% AGY.LN (Allergy Therapeutics £0.02, -0.00) -- positive primary and secondary endpoints of G306 pivotal Phase III trial investigating Grass MATA MPL are highly consistent

        • +13.3% LLQ.SW (Lalique Group CHF31.40, +4.40) -- holder Müller Handels AG Schweiz to raise stake in the company to 25.0% via purchase of shares from chairman

        • +12.8% EGTX.SS (Egetis Therapeutics SEK4.89, +0.61) -- update on the expanded access program for tiratricol (Emcitate) in the USA

        • +9.5% HVO.LN (hVIVO plc £0.22, +0.02) -- £16.8M RSV contract; reports revenue, EBITDA ahead of previous market expectations

        • +9.1% BIOA.B.SS (BioArctic SEK250.20, +22.00) -- Eisai to launch LEQEMBI for the treatment of Alzheimer's Disease in Japan

        • +8.9% SYNT.SS (SyntheticMR SEK23.50, +2.00) -- order

        • +5.5% AKE.FP (Arkema €95.64, +5.06) -- UBS upgrade

        • +5.1% ENT.LN (Entain £8.39, +0.41) -- CEO to step down

        • +5.0% ASA.NO (Atlantic Sapphire NOK1.50, +0.07) -- Sparebank 1 Markets upgrade

        • +4.4% BAS.GR (BASF SE €47.30, +2.02) -- UBS upgrade

        • +3.7% BETCO.SS (Better Collective SEK244.50, +8.50) -- initiated buy at Jefferies

        • +3.6% PAG.LN (Paragon Banking Group £5.87, +0.21) -- RBC Capital Markets upgrade

        • +3.5% FAN.LN (Volution Group £4.20, +0.14) -- trading update

        • +3.1% DHG.ID (Dalata Hotel Group €4.38, +0.14) -- trading update

        • +2.6% VLS.LN (Velocys £0.00, -0.00) -- shareholders to vote on offer from Madison Bidco on 8-Jan

        • +2.0% BOAT.SS (Nimbus Group SEK23.85, +0.45) -- starts sea trials of electrical concept boa

      • Notable Decliners

        • -27.1% TOBII.SS (Tobii SEK5.76, -2.06) -- to launch SEK300M rights issue in 1Q24 to fund acquisition of AutoSense business from Xperi

        • -11.9% AVCT.LN (Avacta Group £1.27, -0.16) -- presents ALS-6000-101 Phase 1a three-weekly dose escalation safety study data

        • -10.7% REVB.LN (Revolution Beauty Group £0.34, -0.04) -- new CFO

        • -9.4% KIT.NO (Kitron NOK29.50, -3.15) -- guides on 2024, 2027

        • -9.2% NEL.NO (NEL ASA NOK6.71, -0.68) -- HyCC cancels previously announced purchase order for 40 MW electrolyser, cites market conditions and client postponing project till 2028; initiated underperform at Santander

        • -7.7% GGP.LN (Greatland Gold £0.09, -0.01) -- drilling and geophysical exploration program results

        • -6.4% WEIR.LN (Weir Group £18.30, -1.23) -- BofA downgrade

        • -6.3% BME.LN (B&M European Value Retail £5.60, -0.38) -- SSA Investments Sarl places ~27.8M B&M European Value Retail shares priced at 582.5/sh via Goldman Sachs and Rothschild -- Bloomberg, citing terms

        • -4.3% BMN.LN (Bushveld Minerals £0.02, -0.00) -- to restructure head office

        • -4.2% STB.NO (Storebrand NOK91.94, -4.00) -- CMD update

        • -3.9% ENOG.LN (Energean £9.58, -0.38) -- holder Kerogen sold 4.4M ordinary shares in the company at 935p/share

        • -3.6% GKP.LN (Gulf Keystone Petroleum £1.07, -0.04) -- operational & corporate update

        • -3.5% PUUILO.FH (Puuilo €8.42, -0.31) -- Q3 earnings

        • -3.2% ORA.FP (Orange €11.01, -0.36) -- EU's deadline to rule on Orange's acquisition of MasMovil extended

        • -3.1% METSO.FH (Metso Corp. €8.46, -0.27) -- BofA downgrade

        • -2.8% AMS.SW (ams-OSRAM CHF1.90, -0.05) -- successful completion of its comprehensive financing plan; in total, ~ €2.25B raised

        • -2.0% REP.SM (Repsol €13.22, -0.27) -- BNP Paribas Exane downgrade

        • -1.9% DNO.NO (DNO ASA NOK9.52, -0.19) -- successful completion of the second appraisal well on the Bergknapp/Åre discoveries in license PL836S

    • EU companies reporting tomorrow:

      • Earnings:

        • DACHs: EVN (EVN.AV), MVV Energie (MVV1.GR)

        • France: Focus Entertainment (ALFOC.FP), Haffner Energy (ALHAF.FP)

        • Nordics: Fluegger Group (FLUG.B.DC)

        • UK: Integrafin Holdings (IHP.LN), Currys (CURY.LN)

  • Data:

    • Economics:

      • Eurozone Oct Industrial Production (6.6%) y/y vs cons (4.6%) and prior revised (6.8%) from (6.9%); (0.7%) m/m vs cons (0.3%) and prior revised to (1.0%) from (1.1%)

      • UK Oct

        • Construction Output +1.1% y/y vs cons +1.2% and prior +2.8%

        • Visible Trade Balance (£17.03B) vs cons (£14.3B) and prior (£14.29B)

        • Industrial Production +0.4% y/y vs cons +1.1% and prior +1.5%; (0.8%) m/m vs cons (0.1%) and prior 0.0%

        • Manufacturing Production +0.8% y/y vs cons +1.9% and prior +3.0%; (1.1%) m/m vs cons 0.0% and prior +0.1%

    • Markets:

      • WTI Crude (24-Jan): +$0.56 or +0.82% to $69.17

      • €-$ (0.0007) or (0.06%) to 1.0787

      • £-$ (0.0036) or (0.29%) to 1.2527

      • €-£ +0.0019 to 0.8611

      • S&P 500 +0.17%

      • Performance year-to-date:

        • FTSE 100: +1.30%

        • DAX: +20.41%

        • CAC: +16.33%

        • MIB: +27.82%

        • Stoxx 600: +11.20%

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE